$ACST READ ASAP Acasti Pharma says 'substantial doubt' on ability to continue as going concern Cash and cash equivalents and short-term investments totaled $14.2M as of March 31, 2020, compared to $25.8M for the year ended March 31, 2019. Acasti believes that existing cash will fully fund the Company's operations into the first calendar quarter of 2021. This means more dilution is coming at some point. Don’t be the last guy holding.
  • 3
3 Likes